Summary of Aytu BioPharma Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Revenue: $15.2 million, down from $16.2 million in Q2 2025.

ADHD Portfolio: $13.2 million, slightly down from $13.8 million year-over-year and flat compared to Q1 2026.

Pediatric Portfolio: $1.7 million, up from $715,000 in Q1 2026 but down from $2.7 million in Q2 2025.

Gross Margin: 63.5%, down from 66.5% in the prior year, primarily due to decreased revenue and transition-related expenses.

Operating Expenses: $11.1 million, up from $10.2 million year-over-year, driven by ExuA launch investments.

Net Loss: $10.6 million, or $1.05 per share, compared to a net income of $800,000 in Q2 2025.

Adjusted EBITDA: Negative $800,000, down from positive $1.3 million in the prior year.

Cash Position: $30 million as of December 31, 2025, down from $32.6 million at the end of Q1 2026.

2Strategic Updates and Business Highlights

ExuA Launch: Aytu has commercially launched ExuA, the first FDA-approved 5-HT1A agonist for Major Depressive Disorder (MDD). The launch strategy focuses on prescriber adoption and brand growth through a motivated sales team and RxConnect platform.

Sales Strategy: The company is employing a mix of personal and non-personal promotion strategies, including a virtual sales team and targeted marketing efforts to high-volume prescribers.

Early Performance: Over 100 doctors have prescribed ExuA within the first month, with positive early feedback from patients regarding tolerability and satisfaction.

3Forward Guidance and Outlook

Revenue Expectations: Aytu anticipates a gradual ramp-up in ExuA net revenue, with initial scripts expected to grow ahead of recognized revenue due to patient access strategies.

Operational Efficiency: The initial launch budget for ExuA has been reduced from $10 million to under $8 million, indicating improved execution efficiency.

Breakeven Point: The company estimates a quarterly breakeven revenue of approximately $17.3 million, with cash breakeven at around $16.6 million.

4Bad News, Challenges, or Points of Concern

Net Loss: The significant net loss and negative adjusted EBITDA reflect the financial impact of the ongoing investments in the ExuA launch and the deemphasis on the ADHD and pediatric portfolios.

Weather Impact: Recent severe weather has affected sales representatives' productivity and prescription fulfillment, potentially hindering early launch momentum.

Generic Competition: The entry of generic competition for Adzenys has begun to impact the ADHD portfolio, although Aytu believes its RxConnect platform will mitigate significant erosion.

5Notable Q&A Insights

Physician Feedback: Early prescribers of ExuA are motivated by the drug's unique mechanism of action and its potential to address unmet needs in patients who have not responded well to existing treatments.

Salesforce Expansion: Expansion of the salesforce is not anticipated in fiscal 2026 until cash flow supports it, emphasizing a cautious approach to scaling operations.

Direct-to-Consumer Campaign: Aytu is exploring web-based marketing strategies, including search engine optimization and social media, to raise awareness of ExuA while being compliant with regulatory requirements. Overall, Aytu BioPharma is navigating a pivotal phase with the launch of ExuA, facing both opportunities and challenges as it seeks to establish its new product in the competitive landscape of MDD treatments.